{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:59:01Z","timestamp":1760403541110,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.ijantimicag.2019.09.004","type":"journal-article","created":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T12:11:34Z","timestamp":1568290294000},"page":"105800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Econometric ARIMA methodology to elucidate the evolution of trends in nosocomial antimicrobial resistance rates in the European Union"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1932-9343","authenticated-orcid":false,"given":"Rafael","family":"Ortega-Huedo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Cuesta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Hoefer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Gonzalez-Zorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2019.09.004_bib0001","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4137\/PMC.S14459","article-title":"Antibiotics and bacterial resistance in the 21st century","volume":"6","author":"Fair","year":"2014","journal-title":"Perspect Medicin Chem"},{"key":"10.1016\/j.ijantimicag.2019.09.004_bib0002","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1128\/CMR.00027-10","article-title":"Hospital epidemiology and infection control in acute-care settings","volume":"24","author":"Sydnor","year":"2011","journal-title":"Clin Microbiol Rev"},{"year":"2014","series-title":"WHO's first global report on antibiotic resistance reveals serious, worldwide threat to public health","key":"10.1016\/j.ijantimicag.2019.09.004_bib0003"},{"year":"2011","series-title":"Tackling antibiotic resistance from a food safety perspective in Europe","author":"World Health Organization","key":"10.1016\/j.ijantimicag.2019.09.004_bib0004"},{"year":"2009","series-title":"Council conclusions on innovative incentives for effective antibiotics","key":"10.1016\/j.ijantimicag.2019.09.004_bib0005"},{"key":"10.1016\/j.ijantimicag.2019.09.004_bib0006","unstructured":"European Parliament resolution of 12 May 2011 on antibiotic resistance. 2011. European Parliament. Strasbourg (France)."},{"key":"10.1016\/j.ijantimicag.2019.09.004_bib0007","unstructured":"Action plan against the rising threats from antimicrobial resistance. 2011.COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL. Brussels (Belgium)."},{"key":"10.1016\/j.ijantimicag.2019.09.004_bib0008","unstructured":"Progress report on the action plan against the rising threats from antimicrobial resistance. 2015. Directorate-General for Health and Food Safety European Comission Brussels (Belgium)."},{"key":"10.1016\/j.ijantimicag.2019.09.004_bib0009","unstructured":"European Commission. European Commission decisions on referral procedures. Brussels: European Commission; n.d. Available at:http:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/index_en.htm(last accessed 16 February 2019)."},{"year":"2009","series-title":"Revised reflection paper on the use of 3rd and 4th generation cephalosporins in food producing animals in the European Union: development of resistance and impact on human and animal health","key":"10.1016\/j.ijantimicag.2019.09.004_bib0010"},{"year":"2006","series-title":"Reflection paper on the use of fluoroquinolones in food producing animals \u2013 precautions for use in the SPC regarding prudent use guidance","author":"Committee for Medicinal Products for Veterinary Use, European Medicines Agency","key":"10.1016\/j.ijantimicag.2019.09.004_bib0011"},{"key":"10.1016\/j.ijantimicag.2019.09.004_bib0012","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.2903\/j.efsa.2011.2322","article-title":"Scientific opinion on the public health risks of bacterial strains producing extended-spectrum \u03b2-lactamases and\/or AmpC \u03b2-lactamases in food and food-producing animals","volume":"9","year":"2011","journal-title":"EFSA J"},{"year":"2012","series-title":"European Commission decision on referral EMEA\/V\/A\/070 regarding veterinary medicinal products containing systemically administered 3rd and 4th generation cephalosporins intended for use in food producing species","key":"10.1016\/j.ijantimicag.2019.09.004_bib0013"},{"year":"2011","series-title":"European Commission decision on referral EMEA\/H\/A-30\/001006 regarding Fortum\u00ae and associated names","key":"10.1016\/j.ijantimicag.2019.09.004_bib0014"},{"year":"2012","series-title":"European Commission decision on referral EMEA\/H\/A-30\/1158 regarding Zinacef\u00ae and associated names","key":"10.1016\/j.ijantimicag.2019.09.004_bib0015"},{"year":"2012","series-title":"European Commission decision on referral EMEA\/H\/A-30\/1157 regarding Zinnat\u00ae and associated names","key":"10.1016\/j.ijantimicag.2019.09.004_bib0016"},{"key":"10.1016\/j.ijantimicag.2019.09.004_bib0017","unstructured":"European Commission. European Commission decision on referral EMEA\/H\/A-30\/1157 regarding Rocephin\u00ae and associated names. Brussels: European Commission; n.d. Available at:http:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/ho25150.htm(last accessed 18 February 2019)."},{"key":"10.1016\/j.ijantimicag.2019.09.004_bib0018","unstructured":"European Comission. Ciprofloxacin referrals. Brussels: European Commission; n.d. Available at:http:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/ho4122.htm(last accessed 18 February 2019)."},{"year":"2008","series-title":"European Commission decision on referral EMEA\/H\/A-31\/914 regarding Norfloxacin","key":"10.1016\/j.ijantimicag.2019.09.004_bib0019"},{"year":"2014","series-title":"European Commission decision on referral EMEA\/V\/A\/89 regarding Enrofloxacin to be administered via the drinking water to chickens and\/or turkeys","key":"10.1016\/j.ijantimicag.2019.09.004_bib0020"},{"year":"2014","series-title":"European Commission decision on referral EMEA\/V\/A\/91 regarding Baytril\u00ae injectable","key":"10.1016\/j.ijantimicag.2019.09.004_bib0021"},{"year":"2014","series-title":"European Comission decision on referral EMEA\/V\/A\/97 regarding Baytril\u00ae injectable","key":"10.1016\/j.ijantimicag.2019.09.004_bib0022"},{"year":"2012","series-title":"European Commission decision on referral EMEA\/V\/A-34\/67 regarding Bayer 10% oral solution enrofloxacin","key":"10.1016\/j.ijantimicag.2019.09.004_bib0023"},{"year":"2010","series-title":"European Commission decision on referral EMEA\/V\/A-35\/49 regarding quinolones and fluoroquinolones","key":"10.1016\/j.ijantimicag.2019.09.004_bib0024"},{"year":"2014","series-title":"Surveillance report: Antimicrobial resistance surveillance in Europe 2014","key":"10.1016\/j.ijantimicag.2019.09.004_bib0025"},{"year":"2017","series-title":"WHO first ever list of antibiotic resistant \u201cpriority pathogens\u201d","key":"10.1016\/j.ijantimicag.2019.09.004_bib0026"},{"year":"2001","series-title":"Directive 2001\/82\/EC of the European Parliament and Council","key":"10.1016\/j.ijantimicag.2019.09.004_bib0027"},{"journal-title":"Strasbourg (France)","article-title":"Directive 2001\/83\/EC of the European Parliament and Council on the community code relating to medicinal products for human use. 2001. European Parliament","year":"2001","key":"10.1016\/j.ijantimicag.2019.09.004_bib0028"},{"year":"2012","series-title":"Communication from the Commission \u2013 Guideline on the details of the various categories of variations to the terms of marketing authorizations for medicinal products for human use and veterinary medicinal products","key":"10.1016\/j.ijantimicag.2019.09.004_bib0029"},{"key":"10.1016\/j.ijantimicag.2019.09.004_bib0030","unstructured":"European Centre for Disease Prevention and Control. Data from the ECDC Surveillance Atlas \u2013 antimicrobial resistance. Stockholm: ECDC; n.d. Available at:https:\/\/ecdc.europa.eu\/en\/antimicrobial-resistance\/surveillance-and-disease-data\/data-ecdc(last accessed 23 February 2019)."},{"key":"10.1016\/j.ijantimicag.2019.09.004_bib0031","first-page":"4872","article-title":"ECDC\/EFSA\/EMA second joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food\u2010producing animals","volume":"15","year":"2017","journal-title":"EFSA J"},{"key":"10.1016\/j.ijantimicag.2019.09.004_bib0032","unstructured":"Eurostat. Population on 1 January by age and sex. n.d. Available accessed 23 February 2019). Statistical Office of the European Union. Luxembourg."},{"year":"1976","series-title":"Time series analysis: forecasting and control","author":"Box","key":"10.1016\/j.ijantimicag.2019.09.004_bib0033"},{"year":"2017","series-title":"Surveillance of antimicrobial resistance in Europe 2016. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net)","key":"10.1016\/j.ijantimicag.2019.09.004_bib0034"},{"key":"10.1016\/j.ijantimicag.2019.09.004_bib0035","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1128\/JCM.00921-13","article-title":"Influence of clinical breakpoint changes from CLSI 2009 to EUCAST 2011 antimicrobial susceptibility testing guidelines on multidrug resistance rates of Gram-negative rods","volume":"51","author":"Hombach","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2019.09.004_bib0036","first-page":"1","article-title":"Community-acquired urinary tract infection by Escherichia coli in the era of antibiotic resistance","volume":"2018","author":"Lee","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.ijantimicag.2019.09.004_bib0037","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1128\/AAC.05411-11","article-title":"Seasonal variations in Clostridium difficile infections are associated with influenza and respiratory syncytial virus activity independently of antibiotic prescriptions: a time series analysis in Qu\u00e9bec, Canada","volume":"56","author":"Gilca","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.09.004_bib0038","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ijantimicag.2018.06.012","article-title":"Colistin resistance in carbapenemase-producing Klebsiella pneumoniae bloodstream isolates: evolution over 15 years and temporal association with colistin use by time series analysis","volume":"52","author":"Tansarli","year":"2018","journal-title":"Int J Antimicrob Agents"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485791930247X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485791930247X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:33:47Z","timestamp":1760376827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092485791930247X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S092485791930247X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.09.004","relation":{},"ISSN":["0924-8579"],"issn-type":[{"type":"print","value":"0924-8579"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Econometric ARIMA methodology to elucidate the evolution of trends in nosocomial antimicrobial resistance rates in the European Union","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105800"}}